Free Trial

Cytek Biosciences (CTKB) Financials

Cytek Biosciences logo
$2.45 -0.03 (-1.21%)
Closing price 04:00 PM Eastern
Extended Trading
$2.57 +0.12 (+4.90%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Cytek Biosciences

Annual Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Income / (Loss) Attributable to Common Shareholders
-6.02 -12 2.58
Consolidated Net Income / (Loss)
-6.02 -12 2.48
Net Income / (Loss) Continuing Operations
-6.02 -12 2.48
Total Pre-Tax Income
-5.70 -16 1.26
Total Operating Income
-21 -28 -1.80
Total Gross Profit
111 109 101
Total Revenue
200 193 164
Operating Revenue
200 193 164
Total Cost of Revenue
89 84 63
Operating Cost of Revenue
89 84 63
Total Operating Expenses
132 137 103
Selling, General & Admin Expense
43 44 35
Marketing Expense
49 49 33
Research & Development Expense
39 44 35
Total Other Income / (Expense), net
15 12 3.06
Interest Expense
-5.24 2.07 2.57
Interest & Investment Income
5.12 6.41 4.62
Other Income / (Expense), net
4.46 7.79 1.02
Income Tax Expense
0.32 -3.56 -1.22
Net Income / (Loss) Attributable to Noncontrolling Interest
0.00 0.00 -0.09
Weighted Average Basic Shares Outstanding
130.61M 135.28M 134.51M
Weighted Average Diluted Shares Outstanding
130.61M 135.28M 138.56M
Weighted Average Basic & Diluted Shares Outstanding
128.10M 130.82M 135.43M

Quarterly Income Statements for Cytek Biosciences

This table shows Cytek Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders
9.64 0.94 -10 -6.17 5.50 -6.46 -4.39 -6.81 3.53 1.67
Consolidated Net Income / (Loss)
9.64 0.94 -10 -6.17 5.50 -6.46 -4.39 -6.81 3.72 1.63
Net Income / (Loss) Continuing Operations
9.64 0.94 -10 -6.17 5.50 -6.46 -4.39 -6.81 3.72 1.63
Total Pre-Tax Income
10 0.16 -7.19 -8.99 4.11 -4.19 -6.60 -9.04 4.11 1.85
Total Operating Income
2.99 -4.25 -8.53 -11 -0.14 -6.42 -9.13 -12 0.08 1.36
Total Gross Profit
34 29 25 23 33 27 28 21 29 27
Total Revenue
57 52 47 45 58 48 50 37 48 40
Operating Revenue
57 52 47 45 58 48 50 37 48 40
Total Cost of Revenue
24 22 21 22 25 21 22 16 19 14
Operating Cost of Revenue
24 22 21 22 25 21 22 16 19 14
Total Operating Expenses
31 33 34 34 33 34 37 33 29 26
Selling, General & Admin Expense
9.07 11 12 11 11 10 11 12 11 8.04
Marketing Expense
12 12 12 13 12 12 14 11 9.03 8.81
Research & Development Expense
9.72 9.88 10 9.80 11 11 12 9.97 9.75 8.65
Total Other Income / (Expense), net
7.34 4.41 1.34 1.74 4.25 2.24 2.53 3.12 4.03 0.49
Interest Expense
-5.93 0.12 0.13 0.44 0.39 0.60 0.41 0.67 0.69 0.65
Interest & Investment Income
0.91 1.43 1.42 1.36 1.45 1.62 1.20 2.14 2.63 1.58
Other Income / (Expense), net
0.49 3.09 0.06 0.82 3.19 1.21 1.74 1.65 2.09 -0.45
Income Tax Expense
0.68 -0.78 3.25 -2.82 -1.39 2.27 -2.21 -2.23 0.40 0.22
Weighted Average Basic Shares Outstanding
130.61M 131.00M 131.44M 130.92M 135.28M 136.17M 135.92M 135.49M 134.51M 134.71M
Weighted Average Diluted Shares Outstanding
130.61M 132.79M 131.44M 130.92M 135.28M 136.17M 135.92M 135.49M 138.56M 138.71M
Weighted Average Basic & Diluted Shares Outstanding
128.10M 128.81M 131.51M 131.27M 130.82M 135.55M 136.36M 135.67M 135.43M 134.85M

Annual Cash Flow Statements for Cytek Biosciences

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Net Change in Cash & Equivalents
-69 -132 -65
Net Cash From Operating Activities
25 5.28 -12
Net Cash From Continuing Operating Activities
25 7.48 -12
Net Income / (Loss) Continuing Operations
-6.02 -12 2.48
Consolidated Net Income / (Loss)
-6.02 -12 2.48
Depreciation Expense
7.21 6.05 2.49
Amortization Expense
-1.93 - 3.09
Non-Cash Adjustments To Reconcile Net Income
18 21 17
Changes in Operating Assets and Liabilities, net
8.03 -7.10 -38
Net Cash From Investing Activities
-83 -94 -56
Net Cash From Continuing Investing Activities
-83 -94 -56
Purchase of Property, Plant & Equipment
-3.53 -4.69 -9.75
Acquisitions
-0.68 -45 -0.12
Purchase of Investments
-274 -176 -46
Sale of Property, Plant & Equipment
0.29 0.00 0.00
Sale and/or Maturity of Investments
195 132 0.00
Net Cash From Financing Activities
-16 -42 5.51
Net Cash From Continuing Financing Activities
-16 -44 5.51
Repayment of Debt
-0.56 -0.57 -0.05
Repurchase of Common Equity
-22 -44 0.00
Issuance of Debt
4.18 0.00 2.98
Other Financing Activities, net
2.17 1.05 2.58
Effect of Exchange Rate Changes
4.53 - -2.49
Cash Income Taxes Paid
3.83 5.31 10

Quarterly Cash Flow Statements for Cytek Biosciences

This table details how cash moves in and out of Cytek Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents
-64 -16 8.78 1.51 3.38 33 -0.85 -167 -42 -8.37
Net Cash From Operating Activities
2.00 13 6.20 3.96 9.51 -4.24 -2.85 2.86 6.19 -7.50
Net Cash From Continuing Operating Activities
2.00 13 6.20 3.96 12 -4.24 -3.44 3.45 6.19 -7.50
Net Income / (Loss) Continuing Operations
9.64 0.94 -10 -6.17 5.50 -6.46 -4.39 -6.81 3.72 1.63
Consolidated Net Income / (Loss)
9.64 0.94 -10 -6.17 5.50 -6.46 -4.39 -6.81 3.72 1.63
Depreciation Expense
1.85 1.85 1.81 1.70 1.63 1.77 1.65 1.00 0.76 0.07
Amortization Expense
-0.69 -0.29 -0.51 -0.44 - -0.77 - - 1.03 0.70
Non-Cash Adjustments To Reconcile Net Income
-3.62 7.46 7.23 7.02 2.13 6.49 7.56 4.50 3.14 5.90
Changes in Operating Assets and Liabilities, net
-5.18 3.26 8.11 1.85 -0.43 -5.27 -6.15 4.75 -2.46 -16
Net Cash From Investing Activities
-63 -16 2.02 -5.75 29 43 2.79 -169 -51 -1.15
Net Cash From Continuing Investing Activities
-63 -16 2.02 -5.75 29 43 2.69 -169 -51 -1.15
Purchase of Property, Plant & Equipment
-0.89 -1.01 -1.05 -0.57 -1.54 -1.33 -1.17 -0.64 -6.53 -1.11
Acquisitions
-0.48 0.01 -0.15 -0.06 -0.06 -0.06 -0.06 -45 -0.08 -0.04
Purchase of Investments
-107 -53 -37 -77 -23 -23 -6.08 -123 -44 -
Sale of Property, Plant & Equipment
0.19 0.02 - - - - - - - -
Sale and/or Maturity of Investments
45 38 40 72 54 68 10 0.00 - -
Net Cash From Financing Activities
-3.64 -12 -1.71 1.61 -34 -8.27 0.22 0.00 3.85 0.16
Net Cash From Continuing Financing Activities
-3.64 -12 -1.71 1.61 -36 -8.27 0.22 0.00 3.85 0.16
Repayment of Debt
-0.14 -0.14 -0.14 -0.14 -0.14 -0.14 -0.14 -0.15 -0.05 -
Repurchase of Common Equity
-6.99 -12 - - -35 -8.43 - - - -
Issuance of Debt
2.79 0.01 -0.00 1.39 - - - 0.00 - -
Other Financing Activities, net
1.71 0.00 0.09 0.36 0.24 0.29 0.37 0.15 0.92 0.16
Effect of Exchange Rate Changes
1.52 -0.94 2.26 1.70 - - - - -1.00 0.13
Cash Income Taxes Paid
1.91 0.86 1.06 0.00 4.50 0.13 0.59 0.09 0.46 2.27

Annual Balance Sheets for Cytek Biosciences

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Total Assets
500 494 519
Total Current Assets
396 392 454
Cash & Equivalents
99 167 297
Restricted Cash
0.03 0.33 2.90
Short-Term Investments
179 95 45
Accounts Receivable
61 56 49
Inventories, net
44 61 48
Prepaid Expenses
14 13 13
Plant, Property, & Equipment, net
18 18 14
Total Noncurrent Assets
85 84 52
Goodwill
17 16 10
Intangible Assets
20 23 4.33
Noncurrent Deferred & Refundable Income Taxes
33 30 20
Other Noncurrent Operating Assets
15 14 17
Total Liabilities & Shareholders' Equity
500 494 519
Total Liabilities
104 101 94
Total Current Liabilities
68 56 49
Accounts Payable
5.53 3.03 4.81
Accrued Expenses
21 20 21
Current Deferred Revenue
25 23 13
Other Current Liabilities
15 10 10
Total Noncurrent Liabilities
36 45 45
Asset Retirement Reserve & Litigation Obligation
9.04 16 16
Noncurrent Deferred Revenue
16 15 13
Other Noncurrent Operating Liabilities
11 14 16
Commitments & Contingencies
0.00 0.00 0.00
Total Equity & Noncontrolling Interests
396 393 426
Total Preferred & Common Equity
396 393 426
Total Common Equity
396 393 426
Common Stock
431 424 443
Retained Earnings
-35 -29 -17
Accumulated Other Comprehensive Income / (Loss)
0.02 -1.28 -0.70

Quarterly Balance Sheets for Cytek Biosciences

This table presents Cytek Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets
491 484 492 519 525 525 499
Total Current Assets
390 384 389 422 425 426 444
Cash & Equivalents
162 178 169 164 132 129 342
Restricted Cash
0.03 0.03 0.35 0.00 0.00 2.92 0.00
Short-Term Investments
116 99 101 124 167 170 -
Accounts Receivable
53 45 50 55 50 43 40
Inventories, net
47 50 55 67 66 70 49
Prepaid Expenses
13 12 13 12 11 11 13
Plant, Property, & Equipment, net
19 18 18 17 16 16 7.84
Total Noncurrent Assets
83 82 85 80 85 83 48
Goodwill
16 16 16 16 19 19 10
Intangible Assets
20 21 22 24 24 25 4.49
Noncurrent Deferred & Refundable Income Taxes
31 30 33 24 26 23 14
Other Noncurrent Operating Assets
15 14 14 15 15 16 19
Total Liabilities & Shareholders' Equity
491 484 492 519 525 525 499
Total Liabilities
106 95 99 104 101 101 83
Total Current Liabilities
63 52 56 59 54 57 41
Accounts Payable
5.39 3.19 3.73 4.71 3.08 5.28 5.64
Accrued Expenses
21 15 18 21 20 20 17
Current Deferred Revenue
25 24 23 23 21 18 12
Other Current Liabilities
11 9.73 11 10 10 13 7.12
Total Noncurrent Liabilities
43 42 44 45 47 45 41
Asset Retirement Reserve & Litigation Obligation
17 17 17 16 16 16 15
Noncurrent Deferred Revenue
15 14 15 15 16 13 10
Other Noncurrent Operating Liabilities
11 11 12 14 15 16 16
Commitments & Contingencies
0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
385 389 393 416 424 423 417
Total Preferred & Common Equity
385 389 393 416 424 423 417
Total Common Equity
385 389 393 416 424 423 417
Common Stock
430 435 430 452 454 448 438
Retained Earnings
-45 -46 -35 -35 -28 -24 -21
Accumulated Other Comprehensive Income / (Loss)
0.10 -0.20 -1.55 -1.58 -1.76 -0.59 -0.53

Annual Metrics And Ratios for Cytek Biosciences

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric 2024 2023 2022
Period end date 12/31/2024 12/31/2023 12/31/2022
Growth Metrics
- - -
Revenue Growth
3.85% 17.67% 28.20%
EBITDA Growth
23.01% -391.97% -45.94%
EBIT Growth
19.90% -2,451.02% -110.30%
NOPAT Growth
26.30% -448.06% -176.19%
Net Income Growth
50.44% -589.05% -17.94%
EPS Growth
0.00% 0.00% 0.00%
Operating Cash Flow Growth
380.57% 143.18% -364.17%
Free Cash Flow Firm Growth
97.23% -54.26% -85.09%
Invested Capital Growth
-9.57% 59.91% 99.91%
Revenue Q/Q Growth
-0.38% 5.41% 25.87%
EBITDA Q/Q Growth
-13.62% 20.47% 123.01%
EBIT Q/Q Growth
2.54% 4.22% 96.90%
NOPAT Q/Q Growth
13.20% -0.80% 78.56%
Net Income Q/Q Growth
40.74% 12.81% 203.54%
EPS Q/Q Growth
0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-22.85% 169.16% 5.74%
Free Cash Flow Firm Q/Q Growth
-157.34% 4.92% 0.00%
Invested Capital Q/Q Growth
9.47% 2.21% 8.68%
Profitability Metrics
- - -
Gross Margin
55.43% 56.69% 61.56%
EBITDA Margin
-5.38% -7.25% 2.92%
Operating Margin
-10.24% -14.43% -1.10%
EBIT Margin
-8.01% -10.39% -0.48%
Profit (Net Income) Margin
-3.00% -6.29% 1.51%
Tax Burden Percent
105.61% 77.33% 197.14%
Interest Burden Percent
35.49% 78.35% -160.31%
Effective Tax Rate
0.00% 0.00% -97.14%
Return on Invested Capital (ROIC)
-11.58% -18.40% -5.82%
ROIC Less NNEP Spread (ROIC-NNEP)
-14.67% -20.82% -7.52%
Return on Net Nonoperating Assets (RNNOA)
10.05% 15.44% 6.42%
Return on Equity (ROE)
-1.53% -2.97% 0.60%
Cash Return on Invested Capital (CROIC)
-1.52% -64.50% -72.45%
Operating Return on Assets (OROA)
-3.23% -3.96% -0.16%
Return on Assets (ROA)
-1.21% -2.40% 0.51%
Return on Common Equity (ROCE)
-1.53% -2.97% 0.60%
Return on Equity Simple (ROE_SIMPLE)
-1.52% -3.09% 0.58%
Net Operating Profit after Tax (NOPAT)
-14 -19 -3.56
NOPAT Margin
-7.17% -10.10% -2.17%
Net Nonoperating Expense Percent (NNEP)
3.09% 2.42% 1.70%
Return On Investment Capital (ROIC_SIMPLE)
-3.63% -4.96% -0.84%
Cost of Revenue to Revenue
44.57% 43.31% 38.44%
SG&A Expenses to Revenue
21.51% 22.78% 21.15%
R&D to Revenue
19.66% 22.87% 21.25%
Operating Expenses to Revenue
65.67% 71.12% 62.66%
Earnings before Interest and Taxes (EBIT)
-16 -20 -0.79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
-11 -14 4.80
Valuation Ratios
- - -
Price to Book Value (P/BV)
2.11 3.15 3.24
Price to Tangible Book Value (P/TBV)
2.33 3.49 3.35
Price to Revenue (P/Rev)
4.17 6.40 8.39
Price to Earnings (P/E)
0.00 0.00 534.49
Dividend Yield
0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.19%
Enterprise Value to Invested Capital (EV/IC)
4.74 7.47 12.67
Enterprise Value to Revenue (EV/Rev)
2.78 5.04 6.30
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 215.35
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
21.99 184.33 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 0.00
Leverage & Solvency
- - -
Debt to Equity
0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00
Financial Leverage
-0.69 -0.74 -0.85
Leverage Ratio
1.26 1.24 1.18
Compound Leverage Factor
0.45 0.97 -1.90
Debt to Total Capital
0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00
Altman Z-Score
5.82 8.30 10.00
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00%
Liquidity Ratios
- - -
Current Ratio
5.86 6.97 9.26
Quick Ratio
5.00 5.66 7.95
Cash Flow Metrics
- - -
Free Cash Flow to Firm (FCFF)
-1.89 -68 -44
Operating Cash Flow to CapEx
784.03% 112.65% -125.47%
Free Cash Flow to Firm to Interest Expense
0.00 -32.99 -17.21
Operating Cash Flow to Interest Expense
0.00 2.55 -4.75
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.29 -8.54
Efficiency Ratios
- - -
Asset Turnover
0.40 0.38 0.33
Accounts Receivable Turnover
3.44 3.68 4.17
Inventory Turnover
1.71 1.53 1.57
Fixed Asset Turnover
11.02 12.03 16.80
Accounts Payable Turnover
20.87 21.33 16.09
Days Sales Outstanding (DSO)
106.08 99.08 87.47
Days Inventory Outstanding (DIO)
214.00 238.05 232.46
Days Payable Outstanding (DPO)
17.49 17.11 22.69
Cash Conversion Cycle (CCC)
302.60 320.02 297.25
Capital & Investment Metrics
- - -
Invested Capital
118 130 81
Invested Capital Turnover
1.62 1.82 2.68
Increase / (Decrease) in Invested Capital
-12 49 41
Enterprise Value (EV)
558 973 1,033
Market Capitalization
836 1,236 1,377
Book Value per Share
$3.07 $2.90 $3.16
Tangible Book Value per Share
$2.79 $2.61 $3.05
Total Capital
396 393 426
Total Debt
0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00
Net Debt
-278 -263 -344
Capital Expenditures (CapEx)
3.24 4.69 9.75
Debt-free, Cash-free Net Working Capital (DFCFNWC)
51 73 61
Debt-free Net Working Capital (DFNWC)
329 336 405
Net Working Capital (NWC)
329 336 405
Net Nonoperating Expense (NNE)
-8.35 -7.34 -6.04
Net Nonoperating Obligations (NNO)
-278 -263 -344
Total Depreciation and Amortization (D&A)
5.28 6.05 5.58
Debt-free, Cash-free Net Working Capital to Revenue
25.39% 37.87% 37.15%
Debt-free Net Working Capital to Revenue
164.02% 173.99% 246.88%
Net Working Capital to Revenue
164.02% 173.99% 246.88%
Earnings Adjustments
- - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
130.61M 135.28M 134.51M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
130.61M 135.28M 138.56M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
128.10M 130.82M 135.43M
Normalized Net Operating Profit after Tax (NOPAT)
-14 -19 -1.26
Normalized NOPAT Margin
-7.17% -10.10% -0.77%
Pre Tax Income Margin
-2.84% -8.14% 0.77%
Debt Service Ratios
- - -
EBIT to Interest Expense
0.00 -9.68 -0.31
NOPAT to Interest Expense
0.00 -9.41 -1.38
EBIT Less CapEx to Interest Expense
0.00 -11.95 -4.09
NOPAT Less CapEx to Interest Expense
0.00 -11.68 -5.17
Payout Ratios
- - -
Dividend Payout Ratio
0.00% 0.00% 0.00%
Augmented Payout Ratio
-358.99% -363.44% 0.00%

Quarterly Metrics And Ratios for Cytek Biosciences

This table displays calculated financial ratios and metrics derived from Cytek Biosciences' official financial filings.

Metric Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics
- - - - - - - - - -
Revenue Growth
-1.30% 7.29% -6.19% 20.96% 20.48% 18.59% 23.74% 5.77% 230.57% 17.75%
EBITDA Growth
-1.11% 109.63% -24.97% 9.00% 18.35% -349.94% -1,502.93% -654.08% 118.28% -37.39%
EBIT Growth
13.67% 77.80% -14.63% 5.70% 40.60% -669.62% -545.15% -284.84% 109.73% -63.46%
NOPAT Growth
1,632.15% -466.55% 6.57% 11.74% -339.81% -475.96% -924.35% -415.99% -99.87% -39.71%
Net Income Growth
75.21% 114.58% -137.78% 9.37% 48.01% -497.05% -525.07% -215.43% 419.14% 14.51%
EPS Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Growth
-79.01% 411.89% 317.68% 38.45% 53.59% 43.51% 69.81% 293.11% 13.67% -746.34%
Free Cash Flow Firm Growth
131.15% 90.15% 110.63% 90.44% -20.54% -20.36% -83.72% -82.73% 0.00% -93.80%
Invested Capital Growth
-9.57% -15.57% -10.74% 0.52% 59.91% 70.04% 104.69% 170.49% 99.91% 183.78%
Revenue Q/Q Growth
11.60% 10.47% 3.92% -22.97% 21.32% -3.41% 33.99% -23.27% 19.42% 0.79%
EBITDA Q/Q Growth
1,042.12% 105.66% 17.13% -284.54% 211.27% 26.56% 39.66% -340.01% 134.99% 312.22%
EBIT Q/Q Growth
400.43% 86.34% 14.56% -424.10% 158.67% 29.44% 29.71% -583.22% 137.70% 179.91%
NOPAT Q/Q Growth
110.96% -326.56% 20.56% -4,027.33% 95.95% 29.66% 24.95% -11,314.47% -93.65% 291.65%
Net Income Q/Q Growth
924.65% 109.02% -69.14% -212.10% 185.24% -47.13% 35.54% -283.08% 128.66% 331.62%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
-84.90% 113.10% 56.79% -58.40% 324.39% -48.74% -199.72% -53.85% 182.53% 20.51%
Free Cash Flow Firm Q/Q Growth
371.97% -174.94% 192.00% 83.39% 14.04% 19.13% 17.19% -109.38% 14.17% -23.44%
Invested Capital Q/Q Growth
9.47% -3.78% -8.42% -6.25% 2.21% 1.72% 3.12% 49.14% 8.68% 22.46%
Profitability Metrics
- - - - - - - - - -
Gross Margin
58.55% 56.32% 54.56% 51.30% 56.75% 56.62% 56.67% 56.72% 60.77% 66.36%
EBITDA Margin
8.07% 0.79% -15.38% -19.29% 8.05% -8.78% -11.55% -25.64% 8.20% 4.17%
Operating Margin
5.20% -8.25% -18.29% -23.93% -0.23% -13.38% -18.37% -32.79% 0.17% 3.36%
EBIT Margin
6.05% -2.25% -18.17% -22.09% 5.25% -10.86% -14.87% -28.34% 4.50% 2.26%
Profit (Net Income) Margin
16.78% 1.83% -22.38% -13.75% 9.45% -13.45% -8.83% -18.35% 7.69% 4.02%
Tax Burden Percent
93.41% 599.36% 145.20% 68.60% 133.86% 154.27% 66.54% 75.30% 90.37% 87.89%
Interest Burden Percent
296.95% -13.57% 84.86% 90.74% 134.43% 80.30% 89.28% 86.01% 189.15% 202.19%
Effective Tax Rate
6.59% -499.36% 0.00% 0.00% -33.86% 0.00% 0.00% 0.00% 9.63% 12.11%
Return on Invested Capital (ROIC)
7.84% -84.60% -21.34% -27.60% -0.57% -16.93% -24.20% -45.79% 0.42% 7.59%
ROIC Less NNEP Spread (ROIC-NNEP)
5.30% -93.94% -19.79% -28.07% -2.44% -16.31% -24.82% -46.31% -0.61% 7.47%
Return on Net Nonoperating Assets (RNNOA)
-3.64% 66.36% 14.02% 19.69% 1.81% 12.34% 19.27% 37.03% 0.52% -6.55%
Return on Equity (ROE)
4.20% -18.25% -7.32% -7.91% 1.24% -4.59% -4.93% -8.76% 0.94% 1.04%
Cash Return on Invested Capital (CROIC)
-1.52% 2.80% -3.89% -15.69% -64.50% -70.97% -83.61% -101.80% -72.45% 0.00%
Operating Return on Assets (OROA)
2.44% -0.89% -7.12% -8.73% 2.00% -3.90% -5.13% -9.31% 1.50% 0.62%
Return on Assets (ROA)
6.77% 0.73% -8.77% -5.43% 3.60% -4.84% -3.05% -6.03% 2.57% 1.10%
Return on Common Equity (ROCE)
4.20% -18.25% -7.32% -7.91% 1.24% -4.59% -4.93% -8.76% 0.94% 1.04%
Return on Equity Simple (ROE_SIMPLE)
0.00% -2.64% -4.51% -2.93% 0.00% -3.35% -1.38% -0.51% 0.00% -0.58%
Net Operating Profit after Tax (NOPAT)
2.79 -25 -5.97 -7.51 -0.18 -4.49 -6.39 -8.51 0.08 1.20
NOPAT Margin
4.85% -49.44% -12.80% -16.75% -0.31% -9.36% -12.86% -22.95% 0.16% 2.95%
Net Nonoperating Expense Percent (NNEP)
2.54% 9.33% -1.55% 0.47% 1.87% -0.62% 0.62% 0.51% 1.03% 0.12%
Return On Investment Capital (ROIC_SIMPLE)
0.70% - - - -0.05% - - - 0.02% -
Cost of Revenue to Revenue
41.45% 43.68% 45.44% 48.70% 43.25% 43.38% 43.33% 43.28% 39.23% 33.64%
SG&A Expenses to Revenue
15.78% 21.25% 25.09% 25.43% 18.47% 21.56% 21.71% 32.57% 21.75% 19.87%
R&D to Revenue
16.92% 19.19% 21.45% 21.84% 18.67% 23.27% 24.42% 26.89% 20.17% 21.37%
Operating Expenses to Revenue
53.35% 64.57% 72.86% 75.23% 56.98% 70.00% 75.04% 89.52% 60.60% 63.00%
Earnings before Interest and Taxes (EBIT)
3.48 -1.16 -8.47 -9.91 3.06 -5.21 -7.39 -11 2.18 0.92
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4.64 0.41 -7.17 -8.65 4.69 -4.21 -5.74 -9.51 3.96 1.69
Valuation Ratios
- - - - - - - - - -
Price to Book Value (P/BV)
2.11 1.89 1.88 2.24 3.15 1.81 2.73 2.94 3.24 4.76
Price to Tangible Book Value (P/TBV)
2.33 2.09 2.08 2.48 3.49 2.01 3.04 3.28 3.35 4.93
Price to Revenue (P/Rev)
4.17 3.62 3.70 4.37 6.40 4.11 6.60 7.49 8.39 15.21
Price to Earnings (P/E)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 534.49 0.00
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.19% 0.00%
Enterprise Value to Invested Capital (EV/IC)
4.74 4.19 4.07 4.97 7.47 3.64 6.86 7.76 12.67 21.87
Enterprise Value to Revenue (EV/Rev)
2.78 2.24 2.30 3.03 5.04 2.54 4.90 5.68 6.30 12.59
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 215.35 0.00
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)
21.99 13.70 29.50 95.20 184.33 236.84 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 136.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency
- - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.69 -0.71 -0.71 -0.70 -0.74 -0.76 -0.78 -0.80 -0.85 -0.88
Leverage Ratio
1.26 1.26 1.24 1.25 1.24 1.22 1.22 1.22 1.18 1.16
Compound Leverage Factor
3.74 -0.17 1.05 1.13 1.67 0.98 1.09 1.05 2.24 2.35
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
5.95 5.21 5.69 6.35 8.46 5.41 7.95 8.42 10.01 15.54
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - -
Current Ratio
5.86 6.21 7.33 6.99 6.97 7.20 7.93 7.53 9.26 10.70
Quick Ratio
5.00 5.26 6.14 5.77 5.66 5.85 6.50 6.05 7.95 9.19
Cash Flow Metrics
- - - - - - - - - -
Free Cash Flow to Firm (FCFF)
15 -5.61 7.49 -8.14 -49 -57 -70 -85 -41 -47
Operating Cash Flow to CapEx
284.07% 1,335.45% 589.17% 697.88% 617.66% -318.72% -242.76% 443.79% 94.84% -676.04%
Free Cash Flow to Firm to Interest Expense
0.00 -47.17 55.90 -18.46 -124.38 -95.82 -172.36 -126.49 -59.18 -72.98
Operating Cash Flow to Interest Expense
0.00 111.10 46.30 8.97 24.14 -7.12 -6.97 4.25 9.01 -11.56
Operating Cash Flow Less CapEx to Interest Expense
0.00 102.78 38.44 7.69 20.23 -9.36 -9.84 3.29 -0.49 -13.27
Efficiency Ratios
- - - - - - - - - -
Asset Turnover
0.40 0.40 0.39 0.40 0.38 0.36 0.35 0.33 0.33 0.27
Accounts Receivable Turnover
3.44 3.72 4.19 4.30 3.68 3.85 4.06 4.52 4.17 3.77
Inventory Turnover
1.71 1.60 1.54 1.44 1.53 1.33 1.26 1.20 1.57 1.49
Fixed Asset Turnover
11.02 11.20 11.73 11.88 12.03 14.50 15.32 15.06 16.80 20.32
Accounts Payable Turnover
20.87 17.96 28.39 19.85 21.33 14.95 14.27 11.42 16.09 11.93
Days Sales Outstanding (DSO)
106.08 97.99 87.01 84.90 99.08 94.72 89.83 80.78 87.47 96.75
Days Inventory Outstanding (DIO)
214.00 228.71 237.36 253.67 238.05 274.21 288.94 305.42 232.46 245.80
Days Payable Outstanding (DPO)
17.49 20.32 12.86 18.39 17.11 24.42 25.57 31.97 22.69 30.59
Cash Conversion Cycle (CCC)
302.60 306.38 311.52 320.18 320.02 344.51 353.20 354.24 297.25 311.96
Capital & Investment Metrics
- - - - - - - - - -
Invested Capital
118 108 112 122 130 128 125 122 81 75
Invested Capital Turnover
1.62 1.71 1.67 1.65 1.82 1.81 1.88 1.99 2.68 2.57
Increase / (Decrease) in Invested Capital
-12 -20 -13 0.63 49 53 64 77 41 49
Enterprise Value (EV)
558 451 455 607 973 465 860 943 1,033 1,640
Market Capitalization
836 729 733 878 1,236 753 1,159 1,245 1,377 1,982
Book Value per Share
$3.07 $2.93 $2.96 $3.00 $2.90 $3.05 $3.13 $3.13 $3.16 $3.09
Tangible Book Value per Share
$2.79 $2.65 $2.68 $2.71 $2.61 $2.75 $2.81 $2.80 $3.05 $2.99
Total Capital
396 385 389 393 393 416 424 423 426 417
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-278 -278 -277 -270 -263 -288 -299 -302 -344 -342
Capital Expenditures (CapEx)
0.70 0.99 1.05 0.57 1.54 1.33 1.17 0.64 6.53 1.11
Debt-free, Cash-free Net Working Capital (DFCFNWC)
51 50 54 63 73 76 72 67 61 61
Debt-free Net Working Capital (DFNWC)
329 327 332 333 336 364 371 369 405 402
Net Working Capital (NWC)
329 327 332 333 336 364 371 369 405 402
Net Nonoperating Expense (NNE)
-6.85 -26 4.47 -1.34 -5.69 1.96 -2.00 -1.71 -3.64 -0.43
Net Nonoperating Obligations (NNO)
-278 -278 -277 -270 -263 -288 -299 -302 -344 -342
Total Depreciation and Amortization (D&A)
1.16 1.56 1.30 1.26 1.63 1.00 1.65 1.00 1.79 0.77
Debt-free, Cash-free Net Working Capital to Revenue
25.39% 24.64% 27.55% 31.20% 37.87% 41.29% 41.23% 40.46% 37.15% 46.69%
Debt-free Net Working Capital to Revenue
164.02% 162.71% 167.77% 165.89% 173.99% 198.57% 211.41% 222.27% 246.88% 308.75%
Net Working Capital to Revenue
164.02% 162.71% 167.77% 165.89% 173.99% 198.57% 211.41% 222.27% 246.88% 308.75%
Earnings Adjustments
- - - - - - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic Shares Outstanding
130.61M 131.00M 131.44M 130.92M 135.28M 136.17M 135.92M 135.49M 134.51M 134.71M
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Diluted Shares Outstanding
130.61M 132.79M 131.44M 130.92M 135.28M 136.17M 135.92M 135.49M 138.56M 138.71M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
128.10M 128.81M 131.51M 131.27M 130.82M 135.55M 136.36M 135.67M 135.43M 134.85M
Normalized Net Operating Profit after Tax (NOPAT)
2.79 -2.97 -5.97 -7.51 -0.10 -4.49 -6.39 -8.51 0.08 1.20
Normalized NOPAT Margin
4.85% -5.77% -12.80% -16.75% -0.16% -9.36% -12.86% -22.95% 0.16% 2.95%
Pre Tax Income Margin
17.96% 0.30% -15.42% -20.05% 7.06% -8.72% -13.27% -24.37% 8.51% 4.57%
Debt Service Ratios
- - - - - - - - - -
EBIT to Interest Expense
0.00 -9.72 -63.19 -22.47 7.76 -8.76 -18.06 -15.62 3.17 1.41
NOPAT to Interest Expense
0.00 -213.96 -44.54 -17.04 -0.46 -7.55 -15.62 -12.65 0.11 1.84
EBIT Less CapEx to Interest Expense
0.00 -18.04 -71.05 -23.76 3.85 -11.00 -20.93 -16.57 -6.34 -0.30
NOPAT Less CapEx to Interest Expense
0.00 -222.28 -52.40 -18.32 -4.37 -9.79 -18.49 -13.61 -9.39 0.13
Payout Ratios
- - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio
-358.99% -485.89% -261.11% 0.00% -363.44% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Cytek Biosciences' Financials

When does Cytek Biosciences's fiscal year end?

According to the most recent income statement we have on file, Cytek Biosciences' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Cytek Biosciences' net income changed over the last 2 years?

Cytek Biosciences' net income appears to be on an upward trend, with a most recent value of -$6.02 million in 2024, falling from $2.48 million in 2022. The previous period was -$12.15 million in 2023. View Cytek Biosciences' forecast to see where analysts expect Cytek Biosciences to go next.

What is Cytek Biosciences's operating income?
Cytek Biosciences's total operating income in 2024 was -$20.52 million, based on the following breakdown:
  • Total Gross Profit: $111.11 million
  • Total Operating Expenses: $131.63 million
How has Cytek Biosciences revenue changed over the last 2 years?

Over the last 2 years, Cytek Biosciences' total revenue changed from $164.04 million in 2022 to $200.45 million in 2024, a change of 22.2%.

How much debt does Cytek Biosciences have?

Cytek Biosciences' total liabilities were at $103.76 million at the end of 2024, a 2.3% increase from 2023, and a 10.5% increase since 2022.

How much cash does Cytek Biosciences have?

In the past 2 years, Cytek Biosciences' cash and equivalents has ranged from $98.72 million in 2024 to $296.60 million in 2022, and is currently $98.72 million as of their latest financial filing in 2024.

How has Cytek Biosciences' book value per share changed over the last 2 years?

Over the last 2 years, Cytek Biosciences' book value per share changed from 3.16 in 2022 to 3.07 in 2024, a change of -2.6%.



This page (NASDAQ:CTKB) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners